spacer
home > ebr > autumn 2017 > signal detection
PUBLICATIONS
European Biopharmaceutical Review

Signal Detection

Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012 and a five year prevalence of 6.23 million. About 400,000 cases per year take place in Europe, 315,000 in the US and 460,000 in the rest of the world (1). This represents about 12% of all new cancer cases and 25% of all cancers in women.

There are three major types of breast cancer, characterised by the presence of key biomarkers: oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). A fourth type, characterised by the lack of all three biomarkers, is informally known as triple-negative.

However, there is another type of breast cancer, which is very aggressive, extremely difficult to diagnose at presentation and ‘hidden’ among ER, PR, HER2 and triple-negative expressing tumours. It used to be referred to as the ‘aggressive type’ and has only recently been named basal-like breast cancer (BLBC) (2-4) (see Figure 1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Partha S Ray obtained his MD degree from Drexel University College of Medicine, US. He went on to complete surgical residency training in the US, followed by a surgical oncology fellowship at the John Wayne Cancer Institute, US. He is currently Professor and Head of Surgical Oncology at HCG Oncology, India.

Dr Roberto Fagnani has a PhD in pharmacology from the University of Milano, Italy. He has academic experience at The National Cancer Institute, US, and the University of California, US. Roberto gained industry experience at Hybritech and Eli Lilly & Co, has had multiple advisory roles at various biotechnology companies and Venture Capital firms and has co-founded three ventures.

spacer
Dr Partha S Ray
spacer
spacer
spacer
Dr Roberto Fagnani
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Prometic Bioseparations are very pleased to introduce their new purpose built ecommerce platform (Webshop)!

Their goal was to build a platform that is easy to navigate, informative and one that makes their products and services easily accessible to researchers and laboratories worldwide. They also wanted to make ordering as quick and easy as possible to meet the needs of the rapidly progressive industry. They have reflected these requirements with an ecommerce store in order to supply high quality products to customers from academia to big pharma.
More info >>

White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 
Industry Events

ACHEMA 2018

11-15 June 2018, Messe Frankfurt GmbH

ACHEMA is the world forum for the process industries, but also an integral part of the trade show calendar of companies specializing in pharma packaging. Every three years 3,800 exhibitors and 170,000 visitors gather in Frankfurt/Main, Germany for the trade show that features everything you need to furnish a chemical or pharma production plant.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement